Citius Oncology, Inc. (CTOR) stock
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.52−0.03 (-5.87%)
Close on Nov 12, 2026Market cap $48.56MP/E –Yield –
Citius Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Citius Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.39M. For fiscal 2025 it was $6.42M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.42M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $218.50K | -76.7% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $1.08M | -65.6% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $1.02M | -19.5% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $1.08M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $938.28K | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $3.14M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $1.26M | – |
See a number that looks wrong?